Lower chemo dose plus blinatumomab for new B-ALL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a lower dose of chemotherapy followed by 14 days of blinatumomab for adults newly diagnosed with a type of leukemia called B-ALL. The goal is to see if this approach works well and reduces side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 15 and 65 years old.
- You have been newly diagnosed with Philadelphia chromosome-negative B-ALL and have not yet had any treatment for it.
- Your general health status allows you to carry out daily activities (ECOG score 0–2).
- Your liver and kidney function, heart function, and certain blood tests are within acceptable ranges.
- You are not pregnant, and you agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug (blinatumomab) with a lower dose of standard chemotherapy for adults newly diagnosed with a certain type of B-cell acute lymphoblastic leukemia. The goal is to see if this approach is effective and causes fewer side effects than full-dose chemotherapy.
This trial tests a combination of low-intensity chemotherapy and a short course of blinatumomab (a targeted immunotherapy) in adults with a certain type of acute leukemia. The goal is to see if this approach helps prepare patients for a stem cell transplant with fewer side effects.
This trial tests a treatment plan for children newly diagnosed with low-risk B-cell ALL. It aims to improve outcomes while reducing side effects.
This trial tests a drug called blinatumomab for people with B-ALL whose leukemia has come back at a very low level (detected only by sensitive testing) after a stem cell transplant. The goal is to see if blinatumomab can clear these remaining leukemia cells and prevent a full relapse.
This trial tests a treatment plan for adults aged 18 to 65 who have just been diagnosed with a type of acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome (Ph-negative). The goal is to see how well this therapy works and how safe it is.
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
Hear when a new Leukemia, Lymphocytic, Acute, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.